3D Medicines (HKG: 1244), a China-based oncology specialist, has entered into a partnership with Sino Cellbiomed, a Qingdao-based cell therapy firm, to collaborate on the development of tumor immunotherapies. Financial terms of the agreement have not been disclosed.
Since its debut on the Hong Kong Stock Exchange in December 2022, 3D Medicines has developed a robust product pipeline featuring 12 drugs, including envafolimab (KN035), a subcutaneous PD-L1 injection currently marketed in China. Founded in 2019, Sino Cellbiomed is focused on developing innovative cell therapies, including its autologous natural strengthening TIL product HS-IT101 and genetically modified super TIL products HS-IT201 and HS-IT301.- Flcube.com
